Statins and blood pressure regulation

Borghi, Claudio; Veronesi, Maddalena; Prandin, Maria Grazia; Dormi, Ada; Ambrosioni, Ettore

doi:10.1007/s11906-001-0090-y

Cited by 48 publications

(20 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with the ACEi alone or in combination with AIIRA or with AIIRA plus cerivastatin maintained SBP at values lower than those of vehicle group, and even of controls. In rats on cerivastatin alone, SBP was lower than in vehicle rats, which is consistent with the antihypertensive effect previously described for statins and attributed to drug interaction with endothelial function or AII receptors (36).…”

Section: Systemic Parameterssupporting

confidence: 89%

How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy

Zoja¹,

Corna²,

Camozzi³

et al. 2002

Journal of the American Society of Nephrology

155

124

View full text Add to dashboard Cite

Abstract. The current therapy for chronic proteinuric nephropathies is angiotensin-converting enzyme inhibitors (ACEi), which slow, but may not halt, the progression of disease, and which may be not effective to the same degree in all patients. In accelerated passive Heymann nephritis (PHN), this study assessed the effect of combining ACEi with angiotensin II receptor antagonist (AIIRA) and with statin that, besides lowering cholesterol, influences inflammatory and fibrogenic processes. Uninephrectomized PHN rats were divided into four groups (n ϭ 10 each) and daily given oral doses of the following: vehicle; 40 mg/L lisinopril; 100 mg/L lisinopril plus L-158,809; 0.3 mg/kg lisinopril plus L-158,809 plus cerivastatin. Treatments started at 2 mo when rats had massive proteinuria and signs of renal injury and lasted until 10 mo. Increases in BP were equally lowered by treatments. ACEi kept proteinuria at levels comparable to pretreatment and numerically lower than vehicle. The addition of AIIRA to lisinopril was more effective, being proteinuria reduced below pretreatment values and significantly lower than vehicle. When cerivastatin was added on top of ACE inhibition and AIIR blockade, urinary protein regressed to normal values and renal failure was prevented. Renal ACE activity was increased threefold in PHN, it was inhibited by more than 60% after ACEi, and decreased below control values with triple therapy. Cerivastatin inhibited ACE activity by 30%. Glomerulosclerosis, tubular damage and interstitial inflammation were ameliorated by ACEi alone or combined with AIIRA, and prevented by addition of statin. TGF-␤ 1 mRNA upregulation in PHN kidney was partially reduced after ACEi or combined with AIIRA and almost normalized after adding statin. Cerivastatin inhibited TGF-␤ 1 gene upregulation by 25%. These data suggest a possible future strategy to induce remission of proteinuria, lessen renal injury, and protect from loss of function in those patients who do not fully respond to ACEi therapy.

show abstract

Section: Systemic Parameterssupporting

confidence: 89%

How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy

Zoja¹,

Corna²,

Camozzi³

et al. 2002

Journal of the American Society of Nephrology

155

124

View full text Add to dashboard Cite

show abstract

“…[45][46][47][48] Both neutral and favourable effects on BP levels have been reported with all HMG-reductase inhibitors (Table 1).…”

Section: Do Lipid Abnormalities Predict the Risk For Hypertension?mentioning

confidence: 99%

Statins: another class of antihypertensive agents?

et al. 2006

View full text Add to dashboard Cite

The assessment of global cardiovascular risk is an essential step in the management of atherosclerotic disease prevention. Among the risk factors to be addressed are hypertension and hyperlipidaemia; these commonly coexist. A neutral or lipid-friendly antihypertensive agent is probably useful in the presence of lipid abnormalities. Similarly, statins have been shown to decrease cardiovascular risk in hypertensive patients. There is also experimental and clinical evidence that statins have blood pressure (BP)-lowering effects. In this review, we discuss the beneficial effects of statins on BP, and provide an overview of the underlying pathophysiology. We also consider the evidence justifying the use of statins in the management of hypertensive patients.

show abstract

“…The actual mechanism of cardiac risk reduction may have factors that are independent of blood pressure reduction, and the benefits of some agents, such as ACE inhibitors, may not be mediated by blood pressure reduction [36]. Some, but not all, studies suggest that improving large vessel elasticity via treatment with statin drugs will reduce SBP [37][38][39].…”

Section: Remaining Questions In Improving Systolic Blood Pressure Conmentioning

confidence: 99%

Uncontrolled hypertension as a risk for coronary artery disease: Patient characteristics and the role of physician intervention

Hyman

Pavlik

2003

Curr Atheroscler Rep

View full text Add to dashboard Cite

Hypertension is the most widely treated cardiovascular risk factor, and there is clear evidence of the efficacy of treating systolic and diastolic blood pressure with existing antihypertensive agents in reducing stroke and cardiac disease. However, only about 25% of the US population has blood pressure controlled to at least 140 mm Hg systolic and 90 mm Hg diastolic. Hypertension control is a complex function of patient and physician behavior. Although poor hypertension control has historically been attributed to lack of health insurance or low utilization of available services, recently published analyses of national survey data and local physician and community samples suggest that physicians have a permissive attitude toward isolated mild systolic blood pressure elevations in the range of 140 to 160 mm Hg. The great majority of participants in health surveys report seeing a physician at least two times per year, and several investigators have documented that physicians are unlikely to increase treatment intensity for systolic elevations alone. Physician inaction toward elevated systolic blood pressure may be due to a reluctance to prescribe multiple drugs and/or lack of belief in the benefits of aggressive treatment to lower systolic blood pressure below 140 mm Hg.

show abstract

Statins and blood pressure regulation

Cited by 48 publications

References 42 publications

How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy

How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy

Statins: another class of antihypertensive agents?

Uncontrolled hypertension as a risk for coronary artery disease: Patient characteristics and the role of physician intervention

Contact Info

Product

Resources

About